Advances in reversible covalent kinase inhibitors

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Drug Discovery

Background:

• Reversible covalent kinase inhibitors (RCKIs) are emerging as a promising therapeutic strategy.
• They combine the selectivity of covalent inhibitors with reduced risk of permanent adverse effects.
• RCKIs are being investigated for various kinases, including the Atypical group, with some candidates in clinical trials.

Purpose of the Study:

• To systematically review advances in Reversible Covalent Kinase Inhibitors (RCKIs).
• To summarize key characteristics including electrophilic groups, chemical scaffolds, nucleophilic residues, and binding modes.
• To provide insights into effective design strategies and future perspectives for RCKI development.

Main Methods:

• Systematic literature review of RCKIs.
• Analysis of electrophilic groups, chemical scaffolds, and nucleophilic residues.
• Examination of binding modes and structure-activity relationships.

Main Results:

• RCKIs demonstrate a range of electrophilic groups and chemical scaffolds.
• Understanding nucleophilic residue distribution is crucial for effective RCKI design.
• Privileged electrophiles and specific binding modes have been identified.

Conclusions:

• RCKIs represent a significant advancement in kinase inhibitor development.
• Effective design strategies leverage insights into electrophiles and nucleophiles.
• Future research directions include expanding RCKI applications beyond kinases.